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Abstract Homocystinuria due to cystathionine b-synthase
deficiency or “classical homocystinuria” is a rare autosomal
recessive condition resulting in altered sulfur metabolism
with elevated methionine and homocysteine in plasma and
homocystine in urine. This condition is characterized by a
high clinical heterogeneity, which contributes to late
clinical diagnosis, usually only made after irreversible
damage has occurred. Treatment is effective if started
before clinical symptoms. The analysis of methionine
levels by tandem mass spectrometry (MS/MS) allows the
newborn screening for homocystinuria, but false-positive
results can be frequently obtained and lead to the unwanted
identification of methionine adenosyl transferase (MAT I/
III) deficiency. This latter condition is biochemically
characterized by isolated persistent hypermethioninemia,
accompanied in some individuals with slightly elevated
levels of homocysteine in plasma. A dominant form of
MAT I/III deficiency, associated with mutation p.R264H,
seems to be very frequent in the Iberian Peninsula and
usually has a clinically benign course. Both these metabolic
disorders are screened in Galicia and Portugal since the
introduction of the MS/MS technology, in 2000 and 2004,
respectively, resulting in the identification of three patients
with classical homocystinuria and 44 patients with MAT I/
III deficiency. All but one heterozygous parent of MAT I/III
patients, identified with the p.R264H mutation, are healthy
adults around the age of 30/40. The implementation of a
second-tier test for homocysteine in dried blood spots
would considerably reduce the number of MAT I/III-
deficient patients identified and improve the specificity
and positive predictive value for classical homocystinuria
screening.
Introduction
Homocystinuria due to cystathionine beta-synthase defi-
ciency (CBSD, OMIM #236200) or “classical homocysti-
nuria” is a rare autosomal recessive condition caused by a
deficiency in the enzyme cystathionine beta-synthase (CBS,
EC 4.2.1.22), the first enzyme in the transsulfuration
pathway. Incidence in Europe is estimated to be 1 in
100,000 live births, with an estimated worldwide frequency
of 1:344,000 (Mudd et al. 2001). CBS catalyzes the
conversion of serine and homocysteine to cystathionine
and water and contains three functional domains; the C-
terminal domain is responsible for allosteric activation of
the enzyme by S-adenosylmethionine (AdoMet); the middle
domain contains the catalytic core, which is responsible for
the pyridoxal 50-phosphate-catalyzed reaction; and the N-
terminal domain, which contains heme, regulates the
enzyme in response to redox conditions (Banerjee and
Zou 2005). CBS is mainly expressed in the adult liver and
pancreas and is active as a homotetramer (Meier et al.
2001); its deficiency results in altered sulfur metabolism
with elevated methionine and homocysteine in plasma and
homocystine in urine. The clinical features of untreated
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homocystinuria due to CBS deficiency result in defects in a
variety of different organs and systems and include myopia,
ectopia lentis, mental retardation, skeletal anomalies resem-
bling Marfan syndrome, and thromboembolic events (Mudd
et al. 2001). There is a high clinical heterogeneity, which
contributes to late clinical diagnosis, usually only made
after irreversible damage has occurred. Treatment is
effective if started before clinical symptoms and is based
on dietary restriction of methionine and supplementation
with betaine, vitamin B12, and folic acid. Without
treatment, 50% of patients die by the age of 30 years,
usually as a result of arterial thromboembolism (Testai and
Gorelick 2010).
This condition is due to mutations in CBS gene, with
more than 170 known mutations, the majority of which
being sporadic mutations (http://cbs.lf1.cuni.cz/). A geno-
type-phenotype correlation is reported, with mutations
associated with residual enzyme activity leading to a milder
clinical phenotype (Mudd et al. 2001).
Patients with classical homocystinuria can be divided
into two important biochemical phenotypes: pyridoxine
responsive and pyridoxine nonresponsive. The pyridoxine-
responsive patients represent approximately 50% of
patients; they usually have milder symptoms and slower
disease progression, when on oral pyridoxine (vitamin B6)
supplementation (Mudd et al. 2001).
The most common CBS allele is c.833T>C (p.I278T),
which is associated with pyridoxine-responsive homocysti-
nuria; this seems to be rare in Iberian Peninsula (20%; Moat
et al. 2004). On the other hand, mutation p.T191M, a
pyridoxine nonresponsive mutation, seems to be prevalent
in this region (Urreizti et al. 2003; Urreitzi et al. 2006).
Mutation p.G307S is also a frequent pyridoxine nonrespon-
sive mutation in northern Europe (Gallagher et al. 1995)
and is probably of Celtic origin.
The analysis of methionine levels by tandem mass
spectrometry (MS/MS) allows newborn screening (NBS)
for homocystinuria, but this method raises two important
issues: milder pyridoxine-responsive patients may be
missed due to slightly elevated levels of methionine at the
screening time, and false-positive results can be obtained
due to secondary methionine elevations, resulting from
other conditions like liver disease, parenteral nutrition, or
methionine adenosyl transferase deficiency (MAT I/III
deficiency, MIM#250850). This latter condition is bio-
chemically characterized by isolated persistent hyperme-
thioninemia accompanied, in some individuals, with
slightly elevated levels of homocysteine in plasma (Mudd
et al. 2001). Methionine adenosyl transferase (MAT, EC
2.5.1.6) is the enzyme responsible for the biosynthesis of S-
adenosylmethionine from methionine and ATP and has two
hepatic forms (MAT I and MAT III) encoded by MAT1A
gene. Although usually inherited as an autosomal recessive
trait, a dominant form has been reported associated with
mutation p.R264H (Chamberlin et al. 1997, 2000).
This mutation has been reported in several populations
(Chamberlin et al. 1997; Nagao et al. 2013; Chien et al.
2005; Chadwick et al. 2014) and seems to be very frequent
in the Iberian Peninsula (Couce et al. 2008, 2013; Martins
et al. 2012). The clinical significance of this condition is
not clearly elucidated, raising some issues regarding its
inclusion in newborn screening programs. Both these
metabolic disorders, classical homocystinuria and MAT I/
III deficiency, are screened in Galicia (Spanish region) and
Portugal since the introduction of the MS/MS technology,
in 2000 and 2004, respectively, resulting in the identifi-
cation of 47 patients, presenting only three of them classical
homocystinuria.
Here, we report a high frequency of MATI/III deficiency
in Iberian Peninsula detected through neonatal screening for
homocystinuria.
Patients and Methods
During the last 10 years, approximately 850,000 newborns
were screened in the single Portuguese Newborn Screening
Laboratory by MS/MS technology, through the analysis of
amino acids and acylcarnitines as butyl esters (Rashed et al.
1995), in dried blood samples. Most samples were collected
between the third and sixth days of life. The positive
screening criterion for classical homocystinuria and MAT I/
III deficiency was a methionine concentration above
50 mmol/L.
Galicia started NBS for both these conditions in 2000,
and approximately 374,000 newborns were screened, using
the same MS/MS method. If the measured concentration
exceeded the 99th centile for the studied population, a
second sample was requested. For methionine, this value
ranged between 48 and 56 mmol/L over the study period. In
Galicia, most of the NBS samples were collected between
the second and sixth days of life, and a urine sample was
also included in the screening. Homocystine measurement
was performed as second-tier test, by MS/MS analysis of
urine spots in filter paper (Rebollido-Fernandez et al.
2012).
In both centers, newborns with a persistent, isolated high
methionine level in a second sample were sent to a
treatment center for further clinical and biochemical
evaluation, which included hepatic function evaluation,
plasma and urinary amino acid chromatography, plasma
total homocysteine, and urinary organic acid analysis.
During this time, 47 patients were identified (Tables 1
and 2); all of them were asymptomatic term newborns.
Diagnosis in all patients was confirmed by MAT1A or CBS
gene analysis. Genomic DNA was isolated from blood
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Table 1 Characterization of patients with MAT I/III deficiency
Patient data
Neonatal
screening time
(blood spot) Confirmation time (plasma) Molecular analysis
Patient Origin Gender
Current
age Age
Met
(mM)a Age
Met
(mM)b
tHcy
(mM)c Gene MAT1A References
1 Portugal F 9 years 6 days 85 12 days 80 13 p.R264H/WT Chamberlin et al.
(1997)
2 Portugal F 8 years 5 days 123 18 days 176 17 p.R264H/WT Chamberlin et al.
(1997)
3 Portugal M 8 years 4 days 77 19 days 121 16 p.R264H/WT Chamberlin et al.
(1997)
4 Portugal M 8 years 4 days 52 19 days 168 16 p.R264H/WT Chamberlin et al.
(1997)
5 Portugal F 7 years 4 days 103 16 days 85 13 p.R264H/WT Chamberlin et al.
(1997)
6 Portugal M 7 years 3 days 58 29 days 247 18 p.R264H/WT Chamberlin et al.
(1997)
7 Portugal F 6 years 4 days 80 30 days 195 14 p.R264H/WT Chamberlin et al.
(1997)
8 Portugal F 6 years 4 days 85 24 days 254 20 p.R264H/WT Chamberlin et al.
(1997)
9 Portugal M 6 years 6 days 309 10 days 194 n.a. p.R264H/WT Chamberlin et al.
(1997)
10 Portugal M 5 years 6 days 73 23 days 145 14 p.R264H/WT Chamberlin et al.
(1997)
11 Portugal F 5 years 6 days 77 63 days 157 12 p.R264H/WT Chamberlin et al.
(1997)
12 Portugal F 5 years 5 days 117 18 days 182 21 p.R264H/WT Chamberlin et al.
(1997)
13 Portugal F 5 years 5 days 124 24 days 155 15 p.R264H/WT Chamberlin et al.
(1997)
14 Portugal F 5 years 7 days 67 30 days 85 5 p.L137V/p.S247N This study
15 Portugal F 5 years 5 days 92 30 days 79 11 p.R264H/WT Chamberlin et al.
(1997)
16 Portugal F 5 years 4 days 79 20 days 111 64 p.R264H/WT Chamberlin et al.
(1997)
17 Portugal F 4 years 3 days 72 19 days 465 n.a. p.L355R/p.L355R Couce et al.
(2013)
18 Portugal F 4 years 6 days 80 22 days 147 23 p.R264H/WT Chamberlin et al.
(1997)
19 Portugal F 4 years 5 days 60 16 days 136 10 p.R264H/WT Chamberlin et al.
(1997)
20 Portugal M 4 years 4 days 100 13 days 105 n.a. p.R264H/WT Chamberlin et al.
(1997)
21 Portugal F 3 years 4 days 63 30 days 117 12 p.R264H/WT Chamberlin et al.
(1997)
22 Portugal F 3 years 5 days 72 19 days 85 11 p.R264H/WT Chamberlin et al.
(1997)
23 Portugal F 3 years 3 days 71 16 days 110 15 p.R264H/WT Chamberlin et al.
(1997)
(continued)
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Table 1 (continued)
Patient data
Neonatal
screening time
(blood spot) Confirmation time (plasma) Molecular analysis
Patient Origin Gender
Current
age Age
Met
(mM)a Age
Met
(mM)b
tHcy
(mM)c Gene MAT1A References
24 Portugal M 2 years 4 days 92 28 days 108 12 p.R264H/WT Chamberlin et al.
(1997)
25 Portugal M 2 years 5 days 101 16 days 94 8 p.R264H/WT Chamberlin et al.
(1997)
26 Portugal F 2 years 6 days 110 23 days 148 12 p.R264H/WT Chamberlin et al.
(1997)
27 Portugal F 1 year, 4
months
5 days 79 21 days 156 12 p.R264H/WT Chamberlin et al.
(1997)
28 Portugal M 1 year 6 days 86 17 days 126 23 p.R264H/WT Chamberlin et al.
(1997)
29 Portugal F 9 months 5 days 71 15 days 90 n.a. p.R264H/WT Chamberlin et al.
(1997)
30 Portugal M 5 months 6 days 71 21 days 113 10 p.R264H/WT Chamberlin et al.
(1997)
31 Portugal M 3 months 4 days 74 16 days 93 26 p.R264H/WT Chamberlin et al.
(1997)
32 Galicia F 8 years 6 days 50 35 days 573 23 p.R264H/WT Chamberlin et al.
(1997)
33 Galicia M 8 years 3 days 100 1 month, 15
days
189 9 p.R264H/WT Chamberlin et al.
(1997)
34 Galicia F 8 years 5 days 88 2 months,
21 days
341 10 p.R264H/WT Chamberlin et al.
(1997)
35 Galicia M 8 years 3 days 147 2 months,
13 days
331 12 p.R264H/WT Chamberlin et al.
(1997)
36 Galicia M 7 years 5 days 100 25 days 164 11 p.R264H/WT Chamberlin et al.
(1997)
37 Galicia F 6 years 3 days 80 1 month, 15
days
292 n.a. p.R264H/WT Chamberlin et al.
(1997)
38 Galicia F 5 years 4 days 115 1 month, 10
days
283 8 p.R264H/WT Chamberlin et al.
(1997)
39 Galicia F 4 years 2 days 82 1 month, 28
days
106 15 p.R264H/WT Chamberlin et al.
(1997)
40 Galicia F 2 years 3 days 82 1 month, 20
days
392 n.a. p.R264H/WT Chamberlin et al.
(1997)
41 Galicia M 2 years 5 days 76 4 months,
8 days
157 8 p.R264H/WT Chamberlin et al.
(1997)
42 Galicia M 1 year,
2 months
6 days 45 3 months 255 12 p.R264H/WT Chamberlin et al.
(1997)
43 Galicia M 2 years 3 days 67 22 days 91 n.a. p.R264H/WT Chamberlin et al.
(1997)
44 Galicia M 5 months 3 days 70 2 months,
22 days
144 11 p.R264H/WT Chamberlin et al.
(1997)
n.a. not available, Met methionine, tHcy total homocysteine
a Cutoff value: 50 mM (Portugal) and 56 mM (Galicia)
b Normal range: 4–44 mM
cNormal range: 2–14 mM; patients 3 and 4 are twin brothers
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samples and sequenced by standard procedures, based on
direct sequencing of PCR-amplified fragments containing
all the coding regions, the corresponding intron-exon
junctions, and the 5’- and 30-untranslated regions (see
Couce et al. 2008 and Martins et al. 2012 for details;
oligonucleotide primer sequences and PCR conditions are
available upon request).
Results
More than one million newborns have been tested for CBS
and MAT I/III deficiencies, in Galicia and Portugal, since
2000, three patients being identified with classical homo-
cystinuria and 44 patients with MAT I/III deficiency. All
patients were confirmed by biochemical and molecular
analysis (Table 1), and we had a 0.013% recall rate due to
elevated methionine in the screening sample; approximately
50% of these cases were premature neonates with parenteral
nutrition.
Thirty-one cases of MAT I/III deficiency (approximate
frequency 1:27,400) and two cases of classical homocysti-
nuria (approximate frequency 1: 425,000) were identified in
Portugal (Tables 1 and 2). Some of these patients were
already reported (Martins et al. 2012; Cozar et al. 2011).
In Galicia, 13 cases of MAT I/III deficiency (approxi-
mate frequency 1:28,736) and one classical homocystinuria
(approximate frequency 1:374,000) were detected (Tables 1
and 2). These patients were already referred to in previous
publications (Urreitzi et al. 2006; Couce et al. 2008, 2013).
All MAT I/III-deficient patients had moderately
increased levels of methionine, both in screening and
confirmation samples, with usually high levels in the
confirmation sample. Most patients with p.R264H mutation
had slightly elevated levels of total homocysteine (Table 1).
In regular annual follow-up, these patients maintain the
moderate methionine levels (data not shown). After
diagnosis, all patients except patients 35 and 38 received
free diets appropriate for their ages with a protein intake
within normal limits (FAO/WHO).
The molecular study of MAT I/III-deficient patients
revealed that 42 of the 44 patients are heterozygous for p.
R264H mutation, with no other mutation identified in
MAT1A gene. Family studies of these patients lead to the
identification of eight new cases and, as expected, one
parent (mother or father) of each patient was also confirmed
to be heterozygote for p.R264H mutation. All these
individuals were clinically well, except the father of patient
15, who died at a young age with a myocardial infarction
(Martins et al. 2012). In general, the identified adult
patients also had mildly elevated levels of homocysteine
and lower levels of methionine, compared with newborns.
Two mothers (of twin brother patients 2 and 3 and patient
28) and one great grandmother (of patient 13) even
presented completely normal levels of methionine (32, 33,
and 49 mM, respectively).
Patient 14 is a heterozygous compound presenting two
novel missense mutations: p.L137V (c.409T>G) and p.
S247N (c.740G>A). This patient has no Iberian ancestry.
Both mutations affect highly conserved amino acid resi-
dues, were not found in dbSNP (www.ncbi.nlm.nih.gov/
projects/SNP/) or exome variant database (evs.gs.washing-
ton.edu/EVS/), and are predicted to be pathogenic through
bioinformatics tools analysis, namely, Condel (bg.upf.edu/
condel/), SIFT (sift.jcvi.org/), MutationTaster (www.muta-
tiontaster.org/), and PolyPhen 2 (genetics.bwh.harvard.edu/
pph2/index.shtml). In the S247 amino acid residue, another
mutation p.S247R (c.739A>C) was recently reported
(Nagao et al. 2013).
Patient 17 is homozygous for mutation p.L355R, a
recently reported mutation found in a related patient living
in Spain (Couce et al. 2013).
Table 2 Characterization of patients with classical homocystinuria
Patient data
Neonatal
screening (blood
spot) Confirmation time (plasma) Molecular study
Patient Origin Gender
Current
age Age
Met
(mM)a Age
Met
(mM)b
tHcy
(mM)c Gene CBS References
45 Portugal F 9 years 5 days 130 22 days 744 130 p.V178GfsX23/
p.K523SfsX18
Cozar et al. (2011),
Castro et al. (2001)
46 Portugal M 2 years 6 days 130 14 days 293 149 p.L338P/p.L338P Urreizti et al. (2003)
47 Galicia F 9 years 3 days 59 29 days 1,086 148 p.T257M/p.T257M Sebastio et al. (1995)
Met methionine, tHcy total homocysteine
a Cutoff value: 50 mM (Portugal) and 56 mM (Galicia)
b Normal range: 4–44 mM
cNormal range: 2–14 mM
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All three patients with classical homocystinuria had
moderately elevated levels of methionine at screening but
extremely high levels of plasma methionine and total
homocysteine at confirmation time (Table 2). They have
been treated since diagnosis in the neonatal period with
dietary restriction of methionine and supplementation with
betaine, vitamin B12, and folic acid. In spite of being
pyridoxine nonresponsive, they remain asymptomatic to
date.
Discussion
Newborn screening has been advocated for classical
homocystinuria due to considerable evidence that early
detection and treatment can prevent the severe clinical
consequences of this condition (Mudd et al. 2001).
Nevertheless, newborn screening for classical homocysti-
nuria has been mostly performed by identification of
increased methionine concentrations in dried blood spot
samples through MS/MS, which is a low-specificity method
if a low cutoff value is used for methionine and a low-
sensitivity method if, instead, a high cutoff value is used
(Gan-Schreier et al. 2010); a compromise value should then
be used, but this is never an optimal strategy for screening.
In Portugal and Galicia, methionine cutoff values of 50 and
56 mmol/L, respectively, have been used, and, as far as we
know, there are no missing cases of homocystinuria.
Moreover, we identified a considerable number of patients
with a possible benign form of MAT I/III deficiency, a
condition not known in the Iberian Peninsula before MS/
MS-based newborn screening. All MAT I/III-deficient
patients are under biochemical and clinical follow-up in
different treatment centers, and all have normal growth,
development, and neurological examination. Only patient 7
was found to have myelination abnormalities of unknown
clinical significance, and in two families (patients 1 and 5),
severe vascular disease histories, without other risk factors,
were observed. Careful regular clinical monitoring is being
performed for all newborn patients and p.R264H carrier
relatives, despite their current healthy state (Martins et al.
2012). This is in accordance with the results of Nagao et al.
(2013), who reported 14 clinically well patients with p.
R264H mutation, mostly detected through newborn screen-
ing. Parents and siblings identified in subsequent family
studies were also clinically well, and there was also a
tendency to a decrease of methionine values with age.
Only three patients were identified with classical
homocystinuria, but they are all free of symptoms proving
the usefulness of this screening.
A second-tier approach for NBS of homocystinuria, by
measuring the total homocysteine on the initial dried blood
spot, has been developed (Gan-Schreier et al. 2010;
Tortorelli et al. 2010). This allows the use of an initial
low cutoff value for methionine, with the positive cases
being then selected for total homocysteine measurement.
With this approach, a higher sensitivity would be achieved,
and the identification of newborns with elevated methionine
levels due to parenteral nutrition or secondary to other liver
disease would be avoided, thus reducing the number of
parents affected by the parental anxiety associated with a
false-positive result. Some of the newborns with MAT I/III
deficiency could also be deliberately ignored, although this
could be controversial due to the incomplete knowledge of
the natural history of the disease in all patients; the
complete lack of MAT I/III activity may represent a risk
for development of brain demyelination (Mudd 2011).
Some MAT I/III-deficient patients have been reported with
myelination disorders (Chamberlin et al. 1996; Furujo et al.
2012; Nagao et al. 2013). Forty-two of the forty-four
patients identified in Portugal and Galicia are heterozygous
for p.R264H mutation, a dominant form of the disease,
associated with a high residual enzyme activity and
moderate elevated methionine levels. According to previous
reports, some residual activity could be sufficient to prevent
clinical symptoms in these patients (Chamberlin et al.
1996). If this is the case, there is no advantage for them to
be identified; they will never need treatment and their
identification will only lead to unnecessary anxiety for the
families. Nevertheless, myelination alterations do not seem
to be directly related to methionine levels, and a genotype/
phenotype correlation regarding methionine levels and CNS
involvement has not yet been established (Chamberlin et al.
1996; Mudd et al. 2001). At least one p.R264H heterozy-
gous 3-year-old girl was reported with myelination abnor-
malities (Martins et al. 2012), which suggests care must be
taken with the assumption that none of these individuals
will develop symptoms.
In spite of the improving of the specificity and positive
predictive value for classical homocystinuria screening, this
second-tier approach may not always allow for the
unequivocal differentiation between MAT I/III deficiency
and classical homocystinuria since there is the possibility of
low levels of total blood homocysteine in the first days of
life in patients with classical homocystinuria B6-responsive
and mildly elevated values of total homocysteine some-
times observed in MAT I/III-deficient patients. Some
patients are initially misdiagnosed as having CBS defi-
ciency due to these mildly elevated values (Nagao et al.
2013). In these cases, the molecular study of MAT1A and
CBS genes or the measurement of other metabolites of the
methionine cycle could be important for the correct
diagnosis (Stabler et al. 2002).
In conclusion, this report tried to address two main
questions: should we maintain NBS for classical homo-
cystinuria through elevated methionine levels, in spite of
118 JIMD Reports
the low frequency of this disease in Iberian Peninsula, and
the identification of a large number of patients with a
possible benign form of MAT I/III deficiency or, on the
other hand, should we implement a second-tier test for total
homocysteine in dried blood spots? Do patients and
families of MAT I/III-deficient patients have any advantage
from their identification or, on the contrary, is this diagnosis
only a burden to the families?
Considering our present knowledge and results, we
decided to implement the second-tier test for total homo-
cysteine. For the MAT I/III-deficient cases which are still to
be identified, careful full information regarding the most
probable benign clinical course of the disease should be
provided to the families, together with the recommendation
for regular clinical and biochemical follow-up.
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